Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

Tc99m-tilmanocept

Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.

PROCEDURE

SPECT Imaging (60 Minutes post-injection)

Subjects enrolled in Groups 1-9 will receive whole body planar SPECT imaging with 3D SPECT or SPECT/CT for targeted joints of interest 60 Minutes post-injection.

PROCEDURE

SPECT Imaging (180 Minutes post-injection)

Subjects enrolled in Groups 1-9 will receive whole body planar SPECT imaging with 3D SPECT or SPECT/CT for targeted joints of interest 180 Minutes post-injection.

PROCEDURE

Whole body planar SPECT imaging (15 Minutes post-injection)

Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 15 minutes post-injection for dosimetry.

PROCEDURE

Whole body planar SPECT imaging (60 Minutes post-injection)

Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 60 minutes post-injection for dosimetry.

PROCEDURE

Whole body planar SPECT imaging (180 Minutes post-injection)

Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 180 minutes post-injection for dosimetry.

PROCEDURE

Whole body planar SPECT imaging (18-20 Hours post-injection)

Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 18-20 Hours post-injection for dosimetry.

PROCEDURE

Blood Collection for PK Testing (15 Mins Before Injection)

Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis within 15 minutes prior to administration of Tc 99m tilmanocept

PROCEDURE

Blood Collection for PK Testing (after injection)

Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis immediately following administration of Tc 99m tilmanocept (00:00)

PROCEDURE

Blood Collection for PK Testing (15 minutes post injection)

Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 15 ± 5 minutes post injection of Tc 99m tilmanocept

PROCEDURE

Blood Collection for PK Testing (60 minutes post injection)

Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 60 ± 15 minutes post injection of Tc 99m tilmanocept

PROCEDURE

Blood Collection for PK Testing (180 minutes post injection)

Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 180 ± 15 minutes post injection of Tc 99m tilmanocept

PROCEDURE

Blood Collection for PK Testing (18-20 hours post injection)

Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 18-20 hours post injection of Tc 99m tilmanocept

PROCEDURE

Planar Image with both Hands in Field of View

Subjects in Groups 1-9 and Groups 10 and 11 will receive planar imaging with both hands in the field of view at 60 and 180 minutes post-injection.

Trial Locations (1)

45429

Kettering Medical Center, Kettering

Sponsors
All Listed Sponsors
lead

Navidea Biopharmaceuticals

INDUSTRY